Kevin Dines
About Kevin Dines
Kevin Dines is the Scientific Senior Director of Preclinical Sciences (Neuroscience TRC) at Bristol Myers Squibb in San Diego, California, with extensive experience in autoimmune, inflammatory, and metabolic dysfunction disorders.
Company
Kevin Dines is currently at Bristol Myers Squibb, a leading global biopharmaceutical company. He operates in San Diego, California, within Bristol Myers Squibb's Neuroscience Translational Research Center (TRC).
Title
Kevin Dines holds the position of Scientific Senior Director, Preclinical Sciences (Neuroscience TRC) at Bristol Myers Squibb, a role he has been serving in since 2020. Previously, he served as Director, Preclinical Sciences (Neuroscience TRC) at the same company from 2019 to 2020.
Work History
Before his current role at Bristol Myers Squibb, Kevin Dines worked as Director, Preclinical Sciences at Receptos, a wholly-owned subsidiary of Celgene, from 2017 to 2019. Prior to that, he served as Associate Director, In Vivo Pharmacology at Receptos, Inc. from 2014 to 2017. He also held the role of Senior Manager of In Vivo Pharmacology at BioTox Sciences from 2010 to 2014. Earlier, he worked as Principal Research Scientist at Tanabe Research Laboratories USA from 2001 to 2010 and as Senior Research Scientist at Trega Biosciences from 1998 to 2000. Additionally, he served as a Research Fellow at the University of California, San Diego from 1994 to 1998.
Education and Expertise
Kevin Dines holds a Ph.D. in Physiology from the University of Aberdeen, where he also completed his B.Sc with Honours in Physiology. His extensive educational background in physiology has underpinned his comprehensive expertise in autoimmune/inflammatory and metabolic dysfunction disorders. He has a demonstrated track record in regulatory filings, due diligence efforts, and external collaborations.
Responsibilities
In his current role, Kevin Dines is responsible for supporting Investigational New Drug (IND) and Clinical Trial Application (CTA) as well as New Drug Application (NDA) regulatory filings and responses. He provides pharmacodynamics (PD) and translational support within Phase 1 clinical trials and is actively involved in early research and development projects at Bristol Myers Squibb.